NCT03083990View on ClinicalTrials.gov

Compare IBI305 and Bevacizumab on Pharmacokinetics/Safety/Immunogenicity on Healthy Male

PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 9, 2017

Primary Completion Date

August 17, 2017

Study Completion Date

August 17, 2017

Conditions
Healthy
Interventions
BIOLOGICAL

IBI305(Bevacizumab Biosimilar)

3mg/kg, infusion in 90minutes

DRUG

Avastin(Bevacizumab)

3mg/kg, infusion in 90minutes

Trial Locations (1)

Unknown

Jilin University First Hospital, Changchun

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT03083990 - Compare IBI305 and Bevacizumab on Pharmacokinetics/Safety/Immunogenicity on Healthy Male | Biotech Hunter | Biotech Hunter